I. Assessment
A. Policy and Research Question
Policy Question:
Should the Philippine government introduce favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?
Research Questions:
- What are the current country TGs or CPGs which recommend the use of favipiravir in treating patients with COVID-19?
- What is the clinical efficacy/ effectiveness and safety of favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens for patients with COVID-19 versusthe DOH-PSMID recommended guidelines as of March 31?
- Does favipiravir as an add-on to the DOH-PSMID-recommended treatment regimens represent value for money for the treatment of patients with COVID-19 versus the DOH-PSMID recommended guidelines as of March 31?
B. Protocol: Not available.
C. Reviewers: Health Technology Assessment Unit, DOH
D. Start of Review: March 26, 2020
E. End of Review: April 8, 2020
II. Recommendation
Evidence summary: Favipiravir
Rapid review: Use of Favipiravir for treating patients with COVID-19
III. Decision
Not Available